Welcome to AstraZeneca
As one of the world's leading pharmaceutical companies, our business is focused on turning good ideas into innovative, effective medicines that make a real difference in important areas of healthcare.-
Latest features
-
Latest news collapse
-
16 November 2009
BRILINTA Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical Setting: Patients with ST-Segment Elevation Myocardial Infarction and Planned Percutaneous Coronary Intervention (PCI)
AstraZeneca today announced results of a PLATO sub-analysis in the most serious type of Acute Coronary Syndrome (ACS) patients, those with ST Segment Elevation Myocardial Infarction (STEMI). In this setting, ST segment elevation indicates total obstruction of a coronary artery which warrants emergency surgery with angioplasty, a procedure termed primary Percutaneous Coronary Intervention or “PCI,” in order to restore flow, salvage the heart muscle (myocardium) from infarction and reduce mortality.
-
13 November 2009
Discovery Research Leader Leaves AstraZeneca
AstraZeneca announced today that Jan M. Lundberg, Executive Vice President, Discovery Research has resigned to pursue other interests outside the company. Jan will step down from his operational role with immediate effect.
-
16 November 2009
BRILINTA Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical Setting: Patients with ST-Segment Elevation Myocardial Infarction and Planned Percutaneous Coronary Intervention (PCI)
